SHILPAMED.NSSHILPAMED.NSNSE
Loading
EBITDA Over TimeExpanding
Percentile Rank100
3Y CAGR+11.7%
5Y CAGR+5.6%
Studio
Year-over-Year Change

Earnings before interest, taxes, depreciation, and amortization

3Y CAGR
+11.7%/yr
vs +5.0%/yr prior
5Y CAGR
+5.6%/yr
Recent acceleration
Acceleration
+6.7pp
Accelerating
Percentile
P100
Near historical high
vs 5Y Ago
1.3x
Solid growth
Streak
2 yr
Consecutive growthExpanding
PeriodValueYoY Change
2025$3.11B+26.4%
2024$2.46B+116.7%
2023$1.13B-49.1%
2022$2.23B-18.2%
2021$2.73B+15.2%
2020$2.37B+30.8%
2019$1.81B-1.3%
2018$1.83B-1.9%
2017$1.87B+11.5%
2016$1.68B-